New Zealand markets open in 6 hours 12 minutes

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
611.25+8.06 (+1.34%)
As of 09:47AM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 72.00B
Enterprise value 68.91B
Trailing P/E 10.72
Forward P/E 14.39
PEG ratio (5-yr expected) 1.21
Price/sales (ttm)5.53
Price/book (mrq)4.17
Enterprise value/revenue 5.09
Enterprise value/EBITDA 8.23

Trading information

Stock price history

Beta (5Y monthly) 0.17
52-week change 317.00%
S&P500 52-week change 316.15%
52-week high 3686.62
52-week low 3441.00
50-day moving average 3632.36
200-day moving average 3587.48

Share statistics

Avg vol (3-month) 3768.9k
Avg vol (10-day) 3846.71k
Shares outstanding 5105.72M
Implied shares outstanding 6107.54M
Float 899.54M
% held by insiders 12.98%
% held by institutions 187.50%
Shares short (30 Dec 2021) 41.64M
Short ratio (30 Dec 2021) 42.17
Short % of float (30 Dec 2021) 41.83%
Short % of shares outstanding (30 Dec 2021) 41.52%
Shares short (prior month 29 Nov 2021) 41.48M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sep 2021

Profitability

Profit margin 52.38%
Operating margin (ttm)53.85%

Management effectiveness

Return on assets (ttm)22.61%
Return on equity (ttm)51.09%

Income statement

Revenue (ttm)13.36B
Revenue per share (ttm)126.60
Quarterly revenue growth (yoy)50.50%
Gross profit (ttm)4.46B
EBITDA 7.47B
Net income avi to common (ttm)7B
Diluted EPS (ttm)62.53
Quarterly earnings growth (yoy)93.80%

Balance sheet

Total cash (mrq)5.79B
Total cash per share (mrq)55.35
Total debt (mrq)2.7B
Total debt/equity (mrq)15.64
Current ratio (mrq)3.71
Book value per share (mrq)163.52

Cash flow statement

Operating cash flow (ttm)5.94B
Levered free cash flow (ttm)3.45B